You are here: Industry Insights > obesity

News List

Obese Men May Have Better Survival With Advanced Prostate Cancer drugs
July 13, 2021
When men have advanced prostate cancer, obesity might offer something of a survival advantage, a preliminary study suggests.
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Assoc prnasia
June 25, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that results of a phase 1 ...
Lumen Bioscience and Novo Nordisk Collaborate on Research of Biologics for Cardiometabolic Disease americanpharmaceuticalreview
June 18, 2021
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for prevalent diseases, will collaborate with Novo Nordisk.
Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China prnasia
June 15, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first ...
AHA News: U.S. Appears to Lose Ground in Controlling High Blood Pressure drugs
June 15, 2021
After years of improvement, high blood pressure control in the U.S. dropped regardless of age, race or ethnicity, according to new research.
Weight-Loss Surgeries Used Least in U.S. States That Need Them Most drugs
June 15, 2021
The American South and Midwest are home to the highest obesity rates in the nation, but a new study reveals that severely obese residents of those regions are the least likely to choose lifesaving weight-loss surgery.
FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity drugs
June 07, 2021
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing.
Social & Health Research Center and Quest Diagnostics Team Up to Address Childhood Hunger and Obesity Exacerbated by COVID-19 in Underserved Communities prnewswire
May 25, 2021
Childhood obesity has disproportionately affected Hispanic and Black communities as a result of negative social determinants of health for years.
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing pharmatimes
May 14, 2021
New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity.
Novo Nordisk plans study of oral semaglutide in obesity pharmatimes
April 23, 2021
Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, the Danish pharma company announced 21st.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page